RESUMO
BACKGROUND: This multicentric, retrospective study conducted within the Italian Rare Cancer Network describes clinical features and explores their possible prognostic relevance in patients with advanced epithelioid haemangioendothelioma (EHE) started on surveillance. PATIENTS AND METHODS: We collected data on adult patients with molecularly confirmed, advanced EHE consecutively referred at five sarcoma reference centres between January 2010 and June 2018, with no evidence of progressive disease (PD) and started on surveillance. Overall survival (OS) and progression-free survival (PFS) univariable and multivariable Cox analyses were performed. In the latter, due to the low number of cases and events, penalized likelihood was applied, and variable selection was performed using a random forest model. RESULTS: Sixty-seven patients were included. With a median follow-up of 50.2 months, 51 (76%) patients developed PD and 16 (24%) remained stable. PD at treatment start did not meet RECIST version 1.1 in 15/51 (29%) patients. The 3-year PFS and OS were 25.4% and 71.1%, respectively, in the whole population. Tumour-related pain (TRP) was the most common baseline symptom (32.8%), followed by temperature (20.9%), fatigue (17.9%), and weight loss (16.4%). Baseline TRP (P = 0.0002), development of TRP during follow-up (P = 0.005), baseline temperature (P = 0.002), and development of fatigue during follow-up (P = 0.007) were associated with a significantly worst PFS. An association between baseline TRP (P < 0.0001), development of TRP during follow-up (P = 0.0009), evidence of baseline serosal effusion (P = 0.121), and OS was recorded. CONCLUSION: Because of the poor outcome observed in EHE patients presenting with serosal effusion, TRP, temperature, or serosal effusion, upfront treatment in this subgroup could be considered.
Assuntos
Hemangioendotelioma Epitelioide , Adulto , Hemangioendotelioma Epitelioide/diagnóstico , Humanos , Itália/epidemiologia , Prognóstico , Critérios de Avaliação de Resposta em Tumores Sólidos , Estudos RetrospectivosRESUMO
PURPOSE: The aim of this double-blind, double-dummy, crossover study was to compare the efficacy, tolerability, and time of onset of analgesia after the administration of 10 mg of morphine hydrochloride via the oral and rectal routes in opioid-naive cancer patients with pain. PATIENTS AND METHODS: Thirty-four patients with cancer pain and no previous opioid treatment were randomized to receive morphine hydrochloride 10 mg orally or rectally (in the form of a microenema) for 2 days. During days 3 and 4, a crossover took place. The scores of pain, nausea, and sedation (visual analog scale of 0 to 100) calculated as the percentage change from baseline (before opioid administration) were assessed at different intervals up to 240 minutes. The number of vomiting episodes was recorded. Parity tests and analysis of variance (ANOVA) were performed to compare the two administration routes. RESULTS: A significant difference in pain intensity was achieved 10 minutes after rectal administration compared with 60 minutes after oral administration. There was still a significant reduction in pain via the rectal route after 180 minutes versus via the oral route after 120 minutes. No significant difference was observed in the intensity of sedation, nausea, or number of vomiting episodes between the oral and rectal routes. CONCLUSION: A liquid solution of morphine is well absorbed via the rectal route. Rectal morphine is safe, effective, easy to manage, and inexpensive, with a rapid onset of action. Rectal morphine can be considered a valid alternative route for opioid administration and may also be used when rescue doses of morphine are required in patients regularly treated with oral or parenteral opioids.
Assuntos
Morfina/administração & dosagem , Neoplasias/fisiopatologia , Dor/tratamento farmacológico , Administração Oral , Administração Retal , Adulto , Idoso , Análise de Variância , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dor/etiologia , Medição da DorRESUMO
We report a clinical multicentre experience with antidepressant agents (trazodone and amitriptyline) in the treatment of chronic pain due to deafferentation. Forty five patients were admitted to the study; most of them with oncological peripheral nerve lesions. Almost all of them were already being treated with NSAID in association with weak or strong opioids. A random double blind study was performed: 23 patients were treated with trazodone, 22 with amitriptyline. In the assessment of results, pain intensity, hours of sleep, hours standing and lying, side effects, mood, anxiety and weakness were all taken into consideration. The therapeutic analgesic efficacy of the two drugs proved to be similar.
Assuntos
Amitriptilina/uso terapêutico , Neuralgia/tratamento farmacológico , Trazodona/uso terapêutico , Adulto , Vias Aferentes/fisiopatologia , Idoso , Amitriptilina/administração & dosagem , Ensaios Clínicos como Assunto , Método Duplo-Cego , Humanos , Pessoa de Meia-Idade , Neuralgia/etiologia , Distribuição Aleatória , Trazodona/administração & dosagemRESUMO
Disturbances caused by skin problems may compromise the quality of life of cancer patients. The main complications affecting the skin comprise the dermatologic toxicity of anticancer therapy, bedsores, malignant ulcers, sores due to nonmetastatic cancer, pruritus, and infections. Most of the information available about these entities has been acquired in the cancer patient without advanced disease. The little currently known about the epidemiology and physiopathology of such lesions in the advanced phase of cancer is presented, and approaches to management are suggested.
Assuntos
Neoplasias/complicações , Dermatopatias/terapia , Assistência Terminal , Humanos , Neoplasias/terapia , Úlcera por Pressão/etiologia , Úlcera por Pressão/prevenção & controle , Úlcera por Pressão/terapia , Prurido/etiologia , Prurido/terapia , Dermatopatias/etiologia , Dermatopatias Infecciosas/etiologia , Dermatopatias Infecciosas/terapia , Úlcera Cutânea/etiologia , Úlcera Cutânea/terapia , Assistência Terminal/métodosRESUMO
Visual disturbances in advanced cancer patients are very rarely signaled, evaluated, or adequately treated. The main causes of sight disturbances are primary eye tumors, ocular metastases, and some paraneoplastic syndromes. Sight alteration can also be associated with asthenia, fatigue, anemia, and hypovitaminosis. These symptoms can be monocular or binocular, and their gravity and evolution can vary. Based on a survey of 156 patients, we estimate the prevalence of visual disturbances to be 12% in advanced cancer patients.
Assuntos
Neoplasias/complicações , Transtornos da Visão/etiologia , Humanos , Transtornos da Visão/epidemiologia , Transtornos da Visão/psicologiaRESUMO
The authors report the data from two studies on the use of controlled-release morphine sulphate tablets for cancer pain relief. This preparation allows just two administrations per day, in comparison with immediate release oral aqueous morphine solution. The first study, a randomized trial carried out on 70 patients suffering from advanced cancer pain, evaluated the analgesic efficacy and side effects of this drug. The second, an open study of 113 patients, assessed analgesic efficacy, incidence of side effects, and the effects of age on dose. The analgesia provided by controlled-release morphine administration proved to be superimposable to those of the oral aqueous morphine solution. Moreover, the use of controlled-release morphine was associated with a statistically significant reduction of some side effects. Ninety-one percent of patients needed controlled-release morphine every 12 hr, while 9% required it every 8 hr.
Assuntos
Morfina/administração & dosagem , Neoplasias/fisiopatologia , Dor/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Preparações de Ação Retardada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Morfina/uso terapêutico , Dor/diagnóstico , Dor/etiologiaRESUMO
Octreotide is a synthetic somatostatin analogue that has been recently tested by various routes of administration as an analgesic drug for different types of pain. The authors evaluated the analgesic efficacy of a subcutaneous 200-ng bolus of octreotide on somatic and visceral pain from advanced cancer in a randomized, single-blind crossover study. The results in nine cases did not show an analgesic effect superior to that of a placebo. Pain relief was obtained in one case of postprandial visceral pain. This case is discussed in detail, and another possible clinical use for octreotide in a particular form of neoplastic pain is hypothesized.
Assuntos
Neoplasias/fisiopatologia , Octreotida/uso terapêutico , Dor/tratamento farmacológico , Analgesia , Neoplasias Ósseas/fisiopatologia , Neoplasias Ósseas/secundário , Humanos , Injeções Subcutâneas , Neoplasias Pulmonares/fisiopatologia , Octreotida/administração & dosagem , Neoplasias Pancreáticas/fisiopatologia , Método Simples-Cego , Fatores de TempoRESUMO
We evaluated the local and systemic tolerability of ketorolac administered through continuous subcutaneous infusion in ten cancer patients. The patients were monitored daily for the severity and duration of pain, and the development of other symptoms. The duration of injection site varied from 1 to more than 7 days. No patients complained of local discomfort or pain. Mild local bleeding at the site of drug injection was observed in seven cases. No increase in the intensity of symptoms was observed during the infusion of ketorolac.
Assuntos
Analgésicos/efeitos adversos , Neoplasias/complicações , Dor Intratável/tratamento farmacológico , Tolmetino/análogos & derivados , Adulto , Idoso , Analgésicos/administração & dosagem , Feminino , Humanos , Infusões Parenterais , Cetorolaco , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Tolmetino/administração & dosagem , Tolmetino/efeitos adversosRESUMO
According to the data of the literature, the prevalence of pain in cancer patients at various stages of the disease and the settings of care range from 38 to 51%, with an increase of up to 74% in the advanced and terminal stages. Despite published World Health Organization (WHO) guidelines for pain management, 42 to 51% of cancer patients receive inadequate analgesia and 30% receive no analgesics at all. A 3-year Research Project "Towards a Pain-free Hospital", which began one year ago, is ongoing at the National Cancer Institute of Milan. The research is organized in three subsequent steps. In the 1st one, a series of patient- and staff-oriented evaluation tools are used to assess the level of appropriateness of pain communication, assessment, management and control of the in-patients. The 2nd step will implement a number of continuing educational interventions aimed at improving patient awareness and staff knowledge of the appropriate pain assessment and management in order to respond to the patient's pain problem. In the 3rd step, all the assessment tools used in step one will be applied again to establish the prevalence of pain, the causes and intensity and patient satisfaction with pain management and to evaluate the impact of the interventions performed during the 2nd step regarding the overall ability of our hospital to tackle pain emergency in the hospitalized cancer population. The results relative to the 1st step are herein reported, in particular as regards the study on prevalence, causes, severity of pain, the interference of pain with sleep, mood and concentration, the use of pain medications and the relief obtained, the structural validity and internal consistency of the assessment tool used. A total of 258 patients hospitalized for at least 24 h were interviewed by 9 physicians using a brief structured questionnaire prepared ad hoc: 51.5% of the patients presented pain during the previous 24 h caused by surgery (49.6%) or by the tumor mass itself (29.3%). Out of the 133 patients with pain, a high degree (much or very much) of pain at rest was present in 27.1% and pain on movement in 30.8%; 31.6% did not take any analgesic treatment, and 14.3% of the latter reported a high degree of pain at rest and 21.4% on movement. Pain interfered with sleep from much to very much in 28.8% and with irritability and nervousness in 15.9% of the patients. In the 91 patients taking analgesics, 57.2% reported a high degree of pain relief. A high degree of pain and interference, however, was associated with low relief levels. The assessment tool used was shown to have a good structural validity and internal consistency (Chrombach alpha index of interference scale = 0.73). Although the Milan Cancer Institute has the longest tradition in Italy of pain assessment by means of validated tools and pain management according to the WHO guidelines and educational efforts in this field, the results of the study clearly show that it is necessary to persevere with continuing educational and informative programs in order to reduce the frequency and severity of pain and thus improve the quality of life of in-patients.
Assuntos
Pacientes Internados , Neoplasias/complicações , Dor/etiologia , Adulto , Idoso , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Medição da Dor , Prevalência , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Inquéritos e QuestionáriosRESUMO
The growing incidence of cancer pathology all over the world implies not only problems of prevention and cure, but also of pain control. Pain appears in more than 50% of cancer patients, mainly because analgesic opioids are not available or adequately administered. For this reason, the World Health Organization (WHO) has created a Collaborating Centre for Cancer Pain Relief at the Division of Pain Therapy of the National Cancer Institute, Milan. Experts in pain therapy have drafted guidelines on the sequential use of analgesic drugs by identifying three steps: non-narcotics, weak narcotics, narcotics, all in association with adjuvant drugs. After a positive pilot trial, field testing will be conducted in developed and developing countries. The first step of the analgesic ladder is represented by the use of non-narcotics; the adequate use of these substances in advanced cancer patients does not exceed 6 months of treatment. Treatment is then either discontinued or changed to a following step because of side-effects (40%) or inefficacy (44%). The reduction in the use of non-narcotics corresponds to a successive increase in the use of opioids, particularly direct agonists. Through an adequate use of the analgesic ladder, pain can be relieved in the great majority of cancer patients.
Assuntos
Analgésicos/uso terapêutico , Neoplasias/complicações , Manejo da Dor , Organização Mundial da Saúde , Humanos , Cuidados PaliativosRESUMO
BACKGROUND: Cancer pain can be treated in most cases with oral analgesics. However, during their clinical history, 53% to 70% of patients will need alternative routes of opioid administration. The rectal administration of opioids is a simple alternative route for many patients. There are no data in the literature regarding the pharmacodynamics and pharmacokinetics of rectal methadone. PATIENTS AND METHODS: We evaluated the analgesia, tolerability and absorption profile of methadone hydrochloride in six opioid-naive cancer patients with pain. A blood sample was collected before administration of a single dose of drug (10 mg) and then again after fixed times. At these fixed times the patients were asked about pain, nausea and drowsiness by means of a visual analogue scale of 0-100 mm (VAS). RESULTS: Pain relief was statistically significant as early as 30 minutes and up to eight hours after methadone administration. None of the patients reported significant side effects. The pharmacokinetics of rectal methadone showed rapid and extensive distribution phases followed by a slow elimination phase. CONCLUSIONS: Rectal methadone can be considered an effective analgesic therapy for patients with cancer pain for whom oral and/or parenteral opioids are not indicated or available.
Assuntos
Analgésicos Opioides/farmacocinética , Neoplasias Colorretais/complicações , Neoplasias de Cabeça e Pescoço/complicações , Metadona/farmacocinética , Dor/tratamento farmacológico , Administração Retal , Adulto , Analgésicos Opioides/efeitos adversos , Neoplasias Colorretais/sangue , Feminino , Neoplasias de Cabeça e Pescoço/sangue , Humanos , Masculino , Metadona/efeitos adversos , Pessoa de Meia-Idade , Dor/sangue , Dor/etiologiaRESUMO
The Authors report a clinical multicentre experience with antidepressant agents (trazodone and amitriptyline) in the treatment of chronic cancer pain with deafferentation component. Forty-five patients were admitted to the study: 27 with oncological peripheral nerve lesions, 6 with post herpetic neuralgias, 10 with not oncological nerve lesions, 2 with central nervous lesions. Almost all of them were already being treated with NSAID associated with weak or strong opioids. A random double blind study was performed: 23 patients were treated with trazodone, 22 with amitriptyline. In the assessment of results, pain intensity, hours of sleep, hours standing and lying, side effects, mood, anxiety, weakness were all taken into consideration. The therapeutic analgesic efficacy of the two drugs proved to be similar.